126 related articles for article (PubMed ID: 20146634)
1. T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.
Coccoris M; Straetemans T; Govers C; Lamers C; Sleijfer S; Debets R
Expert Opin Biol Ther; 2010 Apr; 10(4):547-62. PubMed ID: 20146634
[TBL] [Abstract][Full Text] [Related]
2. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
3. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing.
Govers C; Sebestyén Z; Coccoris M; Willemsen RA; Debets R
Trends Mol Med; 2010 Feb; 16(2):77-87. PubMed ID: 20122868
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
Berry LJ; Moeller M; Darcy PK
Tissue Antigens; 2009 Oct; 74(4):277-89. PubMed ID: 19775368
[TBL] [Abstract][Full Text] [Related]
5. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
6. TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
Pouw N; Treffers-Westerlaken E; Mondino A; Lamers C; Debets R
Mol Immunol; 2010 Apr; 47(7-8):1411-20. PubMed ID: 20303179
[TBL] [Abstract][Full Text] [Related]
7. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
[TBL] [Abstract][Full Text] [Related]
8. Enhanced T cell receptor gene therapy for cancer.
Kieback E; Uckert W
Expert Opin Biol Ther; 2010 May; 10(5):749-62. PubMed ID: 20201709
[TBL] [Abstract][Full Text] [Related]
9. Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells.
Sanchez-Perez L; Gough M; Qiao J; Thanarajasingam U; Kottke T; Ahmed A; Thompson JM; Maria Diaz R; Vile RG
Gene Ther; 2007 Jul; 14(13):998-1009. PubMed ID: 17443216
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen.
Cole DJ; Weil DP; Shilyansky J; Custer M; Kawakami Y; Rosenberg SA; Nishimura MI
Cancer Res; 1995 Feb; 55(4):748-52. PubMed ID: 7531614
[TBL] [Abstract][Full Text] [Related]
11. Cancer therapy with genetically-modified T cells for the treatment of melanoma.
Lagisetty KH; Morgan RA
J Gene Med; 2012 Jun; 14(6):400-4. PubMed ID: 22610729
[TBL] [Abstract][Full Text] [Related]
12. Preclinical development of T cell receptor gene therapy.
Bendle GM; Haanen JB; Schumacher TN
Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
14. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production.
Schaft N; Lankiewicz B; Drexhage J; Berrevoets C; Moss DJ; Levitsky V; Bonneville M; Lee SP; McMichael AJ; Gratama JW; Bolhuis RL; Willemsen R; Debets R
Int Immunol; 2006 Apr; 18(4):591-601. PubMed ID: 16507598
[TBL] [Abstract][Full Text] [Related]
15. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope.
Cole DJ; Weil DP; Shamamian P; Rivoltini L; Kawakami Y; Topalian S; Jennings C; Eliyahu S; Rosenberg SA; Nishimura MI
Cancer Res; 1994 Oct; 54(20):5265-8. PubMed ID: 7522957
[TBL] [Abstract][Full Text] [Related]
16. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
Huang H; Bi XG; Yuan JY; Xu SL; Guo XL; Xiang J
Gene Ther; 2005 Jun; 12(12):999-1010. PubMed ID: 15789061
[TBL] [Abstract][Full Text] [Related]
17. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells.
Sommermeyer D; Uckert W
J Immunol; 2010 Jun; 184(11):6223-31. PubMed ID: 20483785
[TBL] [Abstract][Full Text] [Related]
18. Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes.
Pouw NM; Westerlaken EJ; Willemsen RA; Debets R
J Gene Med; 2007 Jul; 9(7):561-70. PubMed ID: 17471588
[TBL] [Abstract][Full Text] [Related]
19. Genetically modulating T-cell function to target cancer.
Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
[TBL] [Abstract][Full Text] [Related]
20. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
